Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Outlook Therapeutics wins FDA approval for Lytenava in wet AMD

Outlook’s approval brings the first ophthalmic formulation of bevacizumab for the treatment of wet AMD.

Latest news

Sanofi abandons eczema drug approval efforts in another blow to OX40 class

While amlitelimab elicited durable responses in AD, Sanofi does not believe the drug is meaningfully differentiated from current eczema treatment offerings.

Kenvue’s Tylenol with Naproxen gains FDA approval

The combined formulation begins working in under 30 minutes and delivers pain relief for up to 12 hours.

Adult epilepsy market to reach $17.bn across 7MM by 2035

Despite a crowded landscape, there are significant clinical unmet needs in epilepsy treatment.

Biointron introduces RushData platform for AI-driven antibody discovery

RushData incorporates antibody expression, binding analysis, and early developability profiling within one standardised workflow.

BeOne to invest $300m in US manufacturing facility expansion

The new investment increases BeOne Medicines’ total spend on US manufacturing facilities to over $1bn.